

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Comparison of micro-dose human chorionic gonadotropin (hCG) with HMG in PCOS patients with previous Clomiphene Citrate (CC)-resistant anovulation

Protocol summary

Summary

The purpose of this study is to compare the effectiveness of low dose human chorionic gonadotropin (HCG) in combination with Clomiphene citrate to induce ovulation and its endocrine response in patients who had previously failed to ovulate on single Clomiphene citrate therapy. We will also compare the effectiveness and endocrine response of this approach with the regimen of adding HMG to Clomiphene citrate. Infertile women with PCOS, who have shown resistance to Clomiphene Citrate (150 mg- 5 days) in a previous IUI treatment cycle at Royan Institute (Infertility and Reproductive Medicine Research Centre) will be enrolled in this prospective randomized clinical trial study and will be randomly divided into three groups. Control group will receive 100 mg Clomiphene citrate on days 3 to 7 of cycle and 150 mg human menopausal gonadotropin (HMG) during days 7, 8, and 9. An intervention group will receive 100 mg Clomiphene citrate plus 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily when the largest follicle is 12 mm or larger mean diameter. Another intervention group (Group C) will receive 100 mg dose of Clomiphene citrate plus 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily From day 9 (without attention to follicle size). In both experimental groups HCG administration will be continued until the largest follicle is 18-20 mm. Primary outcome measures will be OHSS rate, and multiple pregnancy rate. Other outcome measures are cancellation rate, implantation rate, abortion rate, pregnancy rate, and endometrial status.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138805061141N3**

Registration date: **2009-11-14, 1388/08/23**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2009-11-14, 1388/08/23

Registrant information

Name

Kiandokht Kiani

Name of organization / entity

Royan Institute

Country

Iran (Islamic Republic of)

Phone

+98 21 2230 7960

Email address

kiandokht.kiani@royaninstitute.org

Recruitment status

Recruitment complete

Funding source

Royan Institute Research Centre

Expected recruitment start date

2009-06-01, 1388/03/11

Expected recruitment end date

2011-04-01, 1390/01/12

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of micro-dose human chorionic gonadotropin

(hCG) with HMG in PCOS patients with previous Clomiphene Citrate (CC)-resistant anovulation

Public title

Micro dose HCG in PCOS patients with previous Clomiphene Citrate (CC)-resistant anovulation

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: age under 30 years, primary infertility, PCOS diagnosed by the Rotterdam criteria, by two of the following three features: 1) oligo or anovulation, 2) clinical and/or biochemical signs of hyper androgenism, or 3) polycystic ovaries, previously documented dominant follicle or follicles (R12 mm mean diameter) on transvaginal Ultrasound follicular monitoring, Normal uterine cavity and patent tubes by either hysterosalpingogram or laparoscopy and hysteroscopy, normal fasting glucose and insulin levels, normal serum prolactin, and thyroid stimulating hormone, Estradiol, Progesterone, FSH and dehydroepiandrosterone sulfate levels, normal semen analysis by World Health Organization criteria Exclusion Criteria: previous history of IVF or ICSI treatments, history of hormonal treatment within three month prior to admission (Except OCP, progesterone), history of ovarian cutter or Ovarian drilling, BMI higher than 30, presence of ovarian cyst (more than 30 mm) during third cycle ultrasound

Age

From **18 years** old to **30 years** old

Gender

Female

Phase

1-2

Groups that have been masked

No information

Sample size

Target sample size: **250**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

1

Registry name

ClinicalTrials.gov

Secondary trial Id

NCT00947713

Registration date

2009-07-27, 1388/05/05

Ethics committees

1

Ethics committee

Name of ethics committee

Reproductive Medicine Research Center, Royan Institute, ACECR

Street address

Banihashem square, Eastern Hafez Avenue.

City

Tehran

Postal code

Approval date

1388-06-24, 769/01/-633

Ethics committee reference number

EC/88/1040

Health conditions studied

1

Description of health condition studied

PCOS patients with clomid failure

ICD-10 code

E28.2

ICD-10 code description

Polycystic ovarian syndrome

Primary outcomes

1

Description

Multiple pregnancy rates

Timepoint

one to 10 days after pregnancy test and after BHCG more than 1000

Method of measurement

observation of gestational sac with fetal heart rate by sonography

2

Description

Ovarian hyperstimulation syndrom

Timepoint

at ovum puncture day, at embryo transfer day and three days after embryo transfer

Method of measurement

clinical symptoms, follicle numbers by sonography, serum estradiol level

Secondary outcomes

1

Description

clinical Pregnancy rate

Timepoint

one to ten days after positive serum BHCG

Method of measurement

sonography and observation of gestational sac

2

Description

Implantation rate

Timepoint

1 to 10 days after positive BHCG

Method of measurement

ratio between observed gestational sac and total number of embryo transferred

3

Description

Cancellation rate

Timepoint

after ovarian stimulation, after insemination in lab, after embryo transfer

Method of measurement

lack of follicle or oocyte by sonography, lack of embryo in lab, and OHSS

4

Description

Miscarriage rate

Timepoint

during first 12 weeks after pregnancy

Method of measurement

clinical symptoms and sonographic criteria

5

Description

Endometer stage

Timepoint

at day 9 of cycle, and repeat every 48 hours

Method of measurement

sonography

Intervention groups

1

Description

100 mg Clomiphene citrate on days 3 to 7 of cycle and 150 mg human menopausal gonadotropin (HMG) during days 7, 8, and 9

Category

Treatment - Drugs

2

Description

100 mg Clomiphene citrate plus 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily when the largest follicle is 12 mm or larger mean diameter

Category

Treatment - Drugs

3

Description

100 mg Clomiphene citrate plus 200 IU Human chorionic gonadotropin (hCG; Choriomon; IBSA, Switzerland) intramuscular injection daily From day 9 (without attention to follicle size)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Reproductive Medicine Research Center, Royan Institute, ACECR

Full name of responsible person

Fatemeh Rastegar

Street address

City

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Reproductive Medicine Research Center, Royan Institute, ACECR

Full name of responsible person

Dr. Ahmad Vosoogh

Street address

Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat Highway,

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Reproductive Medicine Research Center, Royan Institute, ACECR

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Reproductive Medicine Research Center, Royan
Institute, ACECR

Full name of responsible person

Dr. Mahnaz Ashrafi

Position

Head of Endocrinology and Female Infertility
Department, Royan Institute/ Gynecologist

Other areas of specialty/work

Street address

Banihashem square, Eastern Hafez Avenue

City

Tehran

Postal code

Phone

+98 21 2356 2000

Fax

Email

ashrafim@royaninstitute.org

Web page address

**Person responsible for scientific
inquiries**

Contact

Name of organization / entity

Reproductive Medicine Research Center, Royan
Institute, ACECR

Full name of responsible person

Dr. Mahnaz Ashrafi

Position

Head of Endocrinology and Female Infertility
Department, Royan Institute/ gynecologist

Other areas of specialty/work

Street address

Banihashem squarae, Eastern Hafez Street

City

Tehran

Postal code

Phone

+98 21 2356 2000

Fax

Email

ashrafim@royaninstitute.org

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Reproductive Medicine Research Center, Royan
Institute, ACECR

Full name of responsible person

Kiandokht Kiani

Position

Researcher/ Master of Science on Midwifery

Other areas of specialty/work

Street address

City

Tehran

Postal code

Phone

Fax

Email

kiani.kiandokht@gmail.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty